Posted by Michael Wonder on 17 Sep 2021
Keytruda made available on the NHS for certain oesophageal cancer patients
17 September 2021 - NICE has recommended MSD’s Keytruda (pembrolizumab) combined with chemotherapy for the first-line treatment of certain oesophageal cancer patients.
Specifically, NICE has approved Keytruda for use in combination with platinum- and fluoropyrimidine-based chemotherapy as an option for untreated inoperable or metastatic carcinoma of the oesophagus, or HER-2 negative gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1.
